论文部分内容阅读
目的:探讨去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病(AML)临床疗效,并观察其对患者生活质量的改善效果,以为患者临床治疗提供选择依据。方法:回顾性分析2012年6月—2015年6月温岭市第一人民医院78例初治AML患者临床诊治情况,其中采用柔红霉素联合阿糖胞苷治疗者为对照组,以去甲氧柔红霉素联合阿糖胞苷治疗者为观察组,各39例。两组均连续治疗7天;统计两组临床疗效及治疗期间所发生的不良反应,随访6个月,并采用Karnofsky功能状态评分标准(KPS)评价患者治疗前、后生活质量情况。结果:治疗及随访期间均无死亡病例,且均完成随访。经治疗6个月后,观察组治疗总有效率61.54%,明显高于对照组30.77%,差异具有统计学意义(P<0.05);观察组治疗期间不良反应率30.77%,明显低于对照组69.23%,差异具有统计学意义(P<0.05)。两组治疗后KPS评分较治疗前均显著升高,然观察组KPS评分升高程度较对照组显著,差异具有统计学意义(P<0.05)。结论:相比柔红霉素联合阿糖胞苷来说,应用去甲柔红霉素联合阿糖胞苷治疗初治急性髓系白血病患者疗效显著,且治疗期间发生不良反应较少,有利于促进其配合治疗,改善其生活质量。
Objective: To investigate the clinical efficacy of deoxyrivaycin combined with cytarabine in the treatment of acute myeloid leukemia (AML) and to observe its effect on improving the quality of life of patients so as to provide a basis for the clinical treatment of patients. Methods: The clinical diagnosis and treatment of 78 patients with newly diagnosed AML in Wenling First People’s Hospital from June 2012 to June 2015 were retrospectively analyzed. Among them, the patients treated with daunorubicin and cytarabine were the control group, Oxyen-Erythromycin combined with cytarabine treatment for the observation group, 39 cases each. The two groups were treated for 7 consecutive days. The clinical efficacy and adverse reactions during the treatment period were observed and followed up for 6 months. The Karnofsky functional status score (KPS) was used to evaluate the quality of life before and after treatment. Results: No deaths were found during the treatment and follow-up. All patients were followed up. After 6 months of treatment, the total effective rate in the observation group was 61.54%, which was significantly higher than that in the control group (30.77%), the difference was statistically significant (P <0.05). The adverse reaction rate in the observation group during treatment was 30.77% 69.23%, the difference was statistically significant (P <0.05). The KPS scores of both groups were significantly higher than those before treatment, but the KPS scores of the observation group were significantly higher than those of the control group (P <0.05). CONCLUSIONS: Compared with daunorubicine and cytarabine, the combination of dextromethorphan and cytarabine in the treatment of patients with newly diagnosed acute myeloid leukemia has a significant effect and fewer adverse reactions during treatment, which is in favor of Promote their cooperation with treatment to improve their quality of life.